Pacira BioSciences (PCRX) Expected to Announce Earnings on Thursday

Pacira BioSciences (NASDAQ:PCRX) will likely be releasing its earnings data before the market opens on Thursday, February 27th. Analysts expect Pacira BioSciences to post earnings of $0.78 per share and revenue of $185.38 million for the quarter.

Pacira BioSciences Stock Performance

Shares of PCRX opened at $25.16 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences has a one year low of $11.16 and a one year high of $31.67. The company has a 50-day simple moving average of $22.49 and a two-hundred day simple moving average of $18.31. The firm has a market capitalization of $1.16 billion, a PE ratio of -12.39 and a beta of 0.80.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on PCRX shares. HC Wainwright reaffirmed a “buy” rating and set a $39.00 target price on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Barclays decreased their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and raised their target price for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Needham & Company LLC raised their price target on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $22.78.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.